3711 Market Street
35 articles with Integral Molecular
Integral Molecular Presents Data on Monoclonal Antibodies (MAbs) Against SLC2A4 (GLUT4), a Critical Target for Diabetes
These rare antibodies were discovered using Integral Molecular's MPS Antibody Discovery platform.
Integral Molecular Reaches Milestone in Immuno-Oncology Target Discovery Collaboration with Daiichi Sankyo
Integral Molecular, the industry leader in discovering antibodies against multipass membrane proteins, today announced that it has successfully reached the first milestone in its collaboration with Daiichi Sankyo Co., Ltd.
Integral Molecular announced the expansion of its two proprietary antibody characterization platforms, Shotgun Mutagenesis Epitope Mapping and the Membrane Proteome Array.
Specific financial terms of the agreement have not been disclosed.
This second collaboration involves the discovery of candidate MAbs against an undisclosed target and leverages the power of Integral Molecular's MPS Antibody Discovery platform.
Integral Molecular's Therapeutic MAbs Against CB1 to Treat NASH Enter New Development Phase Following $1.4M NIH Award
Integral Molecular, the industry leader in antibody discovery against multipass membrane proteins, was awarded $1.4M by the NIH to develop its lead antibodies against cannabinoid receptor 1 (CB1) for treating the liver disease nonalcoholic steatohepatitis (NASH) and metabolic disorders, including obesity and metabolic syndrome.
Integral Molecular, the industry leader in membrane protein technologies, was awarded a Small Business Innovation Research (SBIR) grant from the NIH to initiate a target discovery program for Alzheimer’s disease.
Ebola cases, as well as cases of other significantly lethal viral outbreaks that have occurred has spurred researchers to focus on the development of antivirals that can treat the illnesses.
Integral Molecular celebrates a milestone of mapping 1,000 epitopes for customers, collaborators, and the NIH.
Integral Molecular’s MPS Antibody Discovery Platform Yields Therapeutic Assets for Oncology and Metabolic Syndrome
Integral Molecular announces the development of antibody assets targeting membrane proteins important in oncology (Claudin 6) and metabolic syndrome (GLUT4 and CB1).
Integral Molecular, Inc. Announces Technology Advancement For Discovery Of New Immuno-Oncology Therapeutic Targets
Integral Molecular, Inc. Announces The Expansion Of Its Membrane Proteome Array Technology For Improving Antibody Safety And New Target Discovery
Integral Molecular, Inc. And Integrated BioTherapeutics Initiate Collaboration For Virus Vaccine Discovery
Integral Molecular, Inc. Isolates Zika-Specific Monoclonal Antibodies For Vaccine Research And Diagnostics
Integral Molecular, Inc. Launches Target Specificity Technology To Improve Safety Of Biotherapeutics
Integral Molecular, Inc. Announces Breakthrough In Understanding The Functionality Of Gpcrs, The Largest Class Of Drug Targets In Human Disease
Integral Molecular, Inc. Develops B-Cell Cloning Technology To Discover Rare Antibodies Against Membrane Proteins
Integral Molecular, Inc. Expands Intellectual Property Landscape With International Patents Protecting Key Lipoparticle Technology